PFKFB3 and glioblastoma: explored the possibility of using PFKFB3 inhibitors to address TKI (tyrosine kinase inhibitor) resistance in GBM, suggesting that the combination of PFKFB3 inhibitors and TKIs may bring breakthroughs in clinical practice (82).